In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli

Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01832-18. doi: 10.1128/AAC.01832-18. Print 2019 Jan.

Abstract

The in vitro activity of sulopenem was assessed against a collection from 2014 to 2016 of 539 urinary isolates of Escherichia coli from Canadian patients by using CLSI-defined broth microdilution methodology. A concentration of sulopenem 0.03 µg/ml inhibited both 50% (MIC50) and 90% (MIC90) of isolates tested; sulopenem MICs ranged from 0.015 to 0.25 µg/ml. The in vitro activity of sulopenem was unaffected by nonsusceptibility to trimethoprim-sulfamethoxazole and/or ciprofloxacin, multidrug-resistant phenotypes, extended-spectrum β-lactamases, or AmpC β-lactamases.

Keywords: Escherichia coli; penem; sulopenem; urinary.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Anti-Bacterial Agents / pharmacology*
  • Canada
  • Ciprofloxacin / pharmacology
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Drug Resistance, Multiple, Bacterial / genetics
  • Escherichia coli / drug effects*
  • Escherichia coli / genetics
  • Escherichia coli / isolation & purification
  • Escherichia coli / metabolism
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / microbiology
  • Humans
  • Lactams / pharmacology*
  • Microbial Sensitivity Tests
  • Phenotype
  • Retrospective Studies
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology
  • Urinary Tract Infections / drug therapy
  • Urinary Tract Infections / microbiology

Substances

  • Anti-Bacterial Agents
  • Lactams
  • sulopenem
  • Ciprofloxacin
  • Trimethoprim, Sulfamethoxazole Drug Combination